Skip to main content

Capricor Therapeutics, Inc. (CAPR)

NASDAQ: CAPR · Delayed Price · USD
6.31
+1.29 (25.70%)
Pre-market:Sep 24, 2021 8:00 AM EDT
5.02
0.16 (3.29%)
At close: Sep 23, 4:00 PM
Market Cap114.42M
Revenue (ttm)319,591
Net Income (ttm)-17.99M
Shares Out22.86M
EPS (ttm)-0.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,856,175
Open4.95
Previous Close4.86
Day's Range4.71 - 5.25
52-Week Range3.13 - 8.40
Beta6.54
AnalystsBuy
Price Target10.50 (+109.2%)
Est. Earnings DateNov 11, 2021

About CAPR

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials in...

IndustryBiotechnology
Founded2005
CEOLinda Marban
Employees26
Stock ExchangeNASDAQ
Ticker SymbolCAPR
Full Company Profile

Financial Performance

In 2020, CAPR's revenue was $310,250, a decrease of -69.13% compared to the previous year's $1.01 million. Losses were -$13.66 million, 78.7% more than in 2019.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is 10.50, which is an increase of 109.16% from the latest price.

Price Target
$10.50
(109.16% upside)
Analyst Consensus: Buy

News

Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular ...

–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–

1 hour ago - GlobeNewsWire

Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences

-  Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 -

1 day ago - GlobeNewsWire

Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts

Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?

Other symbols:APRECFMSSPPIVSTM
4 days ago - PennyStocks

Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

-Conference Dates: September 13–15, 2021- -Conference Dates: September 13–15, 2021-

2 weeks ago - GlobeNewsWire

Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World M...

-Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS- -Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Pre...

3 weeks ago - GlobeNewsWire

Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing Start-Up Activities for Pivotal Trial--Phase II, ...

1 month ago - GlobeNewsWire

Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12

Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET

1 month ago - GlobeNewsWire

Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength?

Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

3 months ago - Zacks Investment Research

Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy...

LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based the...

3 months ago - GlobeNewsWire

Capricor Therapeutics to Participate in BIO Digital 2021 Conference

LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...

3 months ago - GlobeNewsWire

Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extrace...

-Capricor's Findings Support Expansion Across Multiple Therapeutic Targets-

4 months ago - GlobeNewsWire

Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

---Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy-

4 months ago - GlobeNewsWire

Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13

Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ET

4 months ago - GlobeNewsWire

Capricor Therapeutics Stock Jumps On Engineered Exosomes Development Pact

Capricor Therapeutics (NASDAQ: CAPR) has signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part of th...

4 months ago - Benzinga

Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Exosomes Platform Technology -Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine--Pipeline Expansion Underway Using Engineered Exosomes-

6 months ago - GlobeNewsWire

Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform

-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles-

6 months ago - GlobeNewsWire

Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines

-Technology Licensed from Johns Hopkins University-

7 months ago - GlobeNewsWire

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes

-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs-

8 months ago - GlobeNewsWire

Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duc...

—Capricor to leverage Lonza's expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply—

8 months ago - GlobeNewsWire

Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients

Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19 Trial Assessing Ability of Capricor's Cardiac Cell Therapy, CAP-1002, t...

8 months ago - GlobeNewsWire

Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript

Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- - Novel Vaccine Induce d Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins - -Deve...

10 months ago - GlobeNewsWire

Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19

Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins

10 months ago - GlobeNewsWire

Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12

Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET

10 months ago - GlobeNewsWire